{"name":"Orphazyme","permalink":"orphazyme","crunchbase_url":"http://www.crunchbase.com/company/orphazyme","homepage_url":"http://www.orphazyme.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":2009,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"contact@orphazyme.com","phone_number":"","description":"","created_at":"Mon Mar 28 01:25:55 UTC 2011","updated_at":"Thu Sep 08 02:46:41 UTC 2011","overview":"<p>Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja JÃ¤Ã¤ttela and Thomas Kirkegaard Jensen from the Danish Cancer Society (KrÃ¦ftens BekÃ¦mpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.</p>","image":{"available_sizes":[[[150,31],"assets/images/resized/0012/8021/128021v1-max-150x150.png"],[[250,51],"assets/images/resized/0012/8021/128021v1-max-250x250.png"],[[386,80],"assets/images/resized/0012/8021/128021v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"CEO","person":{"first_name":"Anders","last_name":"MÃ¸rkeberg Hinsby","permalink":"anders-mrkeberg-hinsby","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$20M","funding_rounds":[{"round_code":"seed","source_url":"http://www.orphazyme.com/news","source_description":"Orphazyme raises 22 mDKK in a seed round extension; Sunstone Capital joins as new investor ","raised_amount":null,"raised_currency_code":"USD","funded_year":2011,"funded_month":2,"funded_day":14,"investments":[{"company":null,"financial_org":{"name":"Sunstone Capital","permalink":"sunstone-capital","image":{"available_sizes":[[[150,64],"assets/images/resized/0003/0832/30832v1-max-150x150.png"],[[171,74],"assets/images/resized/0003/0832/30832v1-max-250x250.png"],[[171,74],"assets/images/resized/0003/0832/30832v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Novo A/S","permalink":"novo-a-s","image":null},"person":null}]},{"round_code":"a","source_url":"http://www.fiercebiotech.com/story/orphazyme-lands-20m-round-back-new-drugs-rare-genetic-disorder/2011-09-07?utm_medium=rss&utm_source=rss","source_description":"Orphazyme lands $20M A round to back new drugs for rare genetic disorder","raised_amount":20000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":9,"funded_day":7,"investments":[{"company":null,"financial_org":{"name":"Aescap Venture","permalink":"aescap-venture","image":{"available_sizes":[[[150,67],"assets/images/resized/0004/9289/49289v2-max-150x150.jpg"],[[168,76],"assets/images/resized/0004/9289/49289v2-max-250x250.jpg"],[[168,76],"assets/images/resized/0004/9289/49289v2-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Novo A/S","permalink":"novo-a-s","image":null},"person":null},{"company":null,"financial_org":{"name":"Sunstone Capital","permalink":"sunstone-capital","image":{"available_sizes":[[[150,64],"assets/images/resized/0003/0832/30832v1-max-150x150.png"],[[171,74],"assets/images/resized/0003/0832/30832v1-max-250x250.png"],[[171,74],"assets/images/resized/0003/0832/30832v1-max-450x450.png"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"Ole MaalÃ¸s Vej 3","address2":"","zip_code":"DK-2200 ","city":"Copenhagen N","state_code":null,"country_code":"DNK","latitude":null,"longitude":null}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}